Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | IDE | P14735 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419895 | 0.78 | GAA (0.46) | NSD2ABL1GAAIDERIN1 | |
| SCHEMBL7342972 | 0.77 | PDE3B (0.45) | IGF1RPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6321766 | 0.74 | CYP1A2 (0.58) | IGF1RCYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL3017686 | 0.74 | CYP1A2 (0.58) | NSD2ABL1GAAIDERIN1 | |
| SCHEMBL3027360 | 0.70 | GAA (0.55) | NSD2ABL1GAAIDERIN1 | |
| SCHEMBL10877244 | 0.70 | L3MBTL1 (0.50) | NSD2ABL1GAAIDERIN1 | |
| SCHEMBL9786600 | 0.69 | NSD2 (0.42) | NSD2ABL1GAAIDERIN1 | |
| SCHEMBL13983006 | 0.69 | ALDH1A1 (0.63) | L3MBTL1IGF1RCYP1A2CYP3A4HPGD | |
| SCHEMBL9786590 | 0.69 | L3MBTL1 (0.48) | NSD2ABL1GAAIDERIN1 | |
| SCHEMBL28601405 | 0.69 | GABRA1 (0.42) | GAATDP1TSHRHSD17B10GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211671-B2 | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-20050075384-A1 | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-07 | — | — | US | disclosed |
| EP-0169164-B1 | IMIDAZOLONECARBONYLARYLIMIDAZOLES; METHOD OF MANUFACTURE, METHOD OF USE AND COMPOSITIONS USEFUL THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-31 | — | — | EP | disclosed |
| EP-0078545-B1 | IMIDAZOLECARBOXYLIC ACID DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-02-03 | — | — | EP | disclosed |
| US-4709043-A | Process for the preparation of imidazolonecarbonylarylimidazoles | SCHERING A.G. (DE) | 1987-11-24 | — | — | US | disclosed |
| EP-0169164-A1 | Imidazolonecarbonylarylimidazoles; method of manufacture, method of use and compositions useful thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-01-22 | — | — | EP | disclosed |
| US-4556665-A | Cardiotonic 1,3-dihydro-4-[[(imidazol-1-yl)aryl]carbonyl]imidazol-2-ones | SCHERING A.G. (DE) | 1985-12-03 | — | — | US | disclosed |
| US-4418071-A | Cardiotonic imidazolecarboxylic acid derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-11-29 | — | — | US | disclosed |
| EP-0078545-A1 | Imidazolecarboxylic acid derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075384-A1 | Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, ADAM33, ADAM8 | NSD2 3951/4885ABL1 1895/4885GAA 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.